T1 and T2 bladder cancer: selecting optimal therapy.
Soloway
M S
MS
Department of Urology, University of Miami, School of Medicine, FL 33101, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine